XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.03
+3.35%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-11.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 2, 2026 | Houvras Yariv · officer: CHIEF MEDICAL OFFICER | A-Award | 105,000 | $8.91 |
| Jun 12, 2026 | Xu Yuan · director | A-Award | 5,000 | $7.99 |
| Jun 12, 2026 | ROSS ROBERT W. · director | A-Award | 5,000 | $7.99 |
| Jun 12, 2026 | Bonstein Sara · director | A-Award | 5,000 | $7.99 |
| Jun 12, 2026 | Brennan Aoife · director | A-Award | 5,000 | $7.99 |
| Jun 12, 2026 | Curran Daniel J. · director | A-Award | 5,000 | $7.99 |
| Jun 12, 2026 | Shannon James Samuel · director | A-Award | 5,000 | $7.99 |
| Jun 12, 2026 | Bello Akintunde Olatokumbo · director | A-Award | 5,000 | $7.99 |
| Apr 16, 2026 | Blanchard Cheryl R · director | A-Award | 10,000 | $8.40 |
| Mar 30, 2026 | Shannon James Samuel · director | Purchase | 5,000 | $8.79 |
| Feb 17, 2026 | GILEAD SCIENCES, INC. · 10 percent owner | Purchase | 3,739,000 | $0.00 |
| Jan 5, 2026 | Russo Rene · director, officer: PRESIDENT AND CEO | A-Award | 1,500,258 | $0.84 |
| Jan 5, 2026 | Frankenfield Christopher James · officer: Chief Financial Officer | Sale | 7,030 | $0.64 |
| Jan 5, 2026 | Russo Rene · director, officer: PRESIDENT AND CEO | M-Exempt | 44,250 | $0.00 |
| Jan 5, 2026 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 451,885 | $0.84 |
| Jan 5, 2026 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | M-Exempt | 16,625 | $0.00 |
| Jan 5, 2026 | Brennan Kevin M. · officer: SVP, FINANCE AND ACCOUNTING | A-Award | 95,221 | $0.84 |
| Jan 5, 2026 | Brennan Kevin M. · officer: SVP, FINANCE AND ACCOUNTING | M-Exempt | 5,000 | $0.00 |
| Jan 5, 2026 | Brennan Kevin M. · officer: SVP, FINANCE AND ACCOUNTING | Sale | 1,826 | $0.64 |
| Jan 5, 2026 | Frankenfield Christopher James · officer: Chief Financial Officer | A-Award | 668,789 | $0.84 |
| Jan 5, 2026 | Frankenfield Christopher James · officer: Chief Financial Officer | M-Exempt | 19,375 | $0.00 |
| Nov 25, 2025 | Russo Rene · director, officer: PRESIDENT AND CEO | A-Award | 150,000 | $1.50 |
| Nov 25, 2025 | Frankenfield Christopher James · officer: Chief Financial Officer | A-Award | 20,000 | $1.50 |
| Nov 25, 2025 | Brennan Kevin M. · officer: SVP, FINANCE AND ACCOUNTING | A-Award | 20,000 | $1.00 |
| Nov 25, 2025 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 625,000 | $0.84 |
| Nov 25, 2025 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 106,000 | $1.50 |
| Nov 25, 2025 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 44,210 | $1.50 |
| Nov 25, 2025 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 35,000 | $1.50 |
| Nov 25, 2025 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 25,000 | $1.50 |
| Nov 25, 2025 | Luptakova Katarina · officer: CHIEF MEDICAL OFFICER | A-Award | 15,000 | $1.50 |
Institutional positioning
13F filings over the trailing two quarters
New 18Increased 5Reduced 19Sold out 8
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Reduced | 664,021 | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | Unchanged | 664,021 | Aug 14, 2026 |
| GILEAD SCIENCES, INC. | Reduced | 650,389 | May 8, 2026 |
| ORBIMED ADVISORS LLC | New Position | 592,300 | Aug 14, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Reduced | 422,505 | May 15, 2026 |
| Frazier Life Sciences Management, L.P. | Unchanged | 422,505 | Aug 14, 2026 |
| Stonepine Capital Management, LLC | Increased | 225,994 | Aug 17, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 178,517 | Aug 13, 2026 |
| Sio Capital Management, LLC | Unchanged | 152,464 | Aug 14, 2026 |
| SIO CAPITAL MANAGEMENT, LLC | Reduced | 152,464 | May 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 123,660 | May 15, 2026 |
| CALIGAN PARTNERS LP | New Position | 112,128 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | New Position | 111,541 | Aug 14, 2026 |
| Merck & Co., Inc. | Unchanged | 105,982 | Aug 7, 2026 |
| MERCK & CO., INC. | Reduced | 105,982 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 2, 2026